Something notable happened on Friday, indicating the accelerating institutionalization of the bitcoin BTC$77,557.88 market, which has been pioneered by everyday people for years.

This is because options, or hedging instruments, linked to BlackRock’s bitcoin exchange-traded fund (ETF), IBIT, have grown slightly larger on Nasdaq than total bitcoin options trading on the offshore giant Deribit. It is particularly striking that IBIT options have, in just two years, closed the gap with Deribit’s bitcoin options market, which has been operating since 2016.

On Friday, the dollar value of open or active IBIT options contracts on Nasdaq, the so-called open interest (OI), was $27.61 billion, slightly higher than the $26.90 billion in Deribit’s bitcoin options, according to data tracked by decentralized crypto volatility protocol Volmex.

This milestone indicates that the regulated, institutional-grade bitcoin investment and derivatives infrastructure in the U.S. is no longer second fiddle to the offshore market. Moreover, a booming, regulated market in the U.S. could embolden more Wall Street institutions to explore digital assets, ultimately leading to more mature price discovery.

Deribit’s Global Head of Retail Sales and Business, Sidrah Fariq, described IBIT’s rise as a net positive for the broader crypto derivatives ecosystem.

“US retail can’t onboard platforms like Deribit, so iShares Bitcoin Trust (IBIT) options give them direct access to regulated leverage and options exposure. This is further supported by the current macro environment with supply chain uncertainty, energy shocks, and broader geopolitical risks, which naturally drives demand for hedging and options strategies,” Fariq told CoinDesk.

What are options?

Options are derivative contracts that give the purchaser the right to buy or sell the underlying asset at a predetermined price at a later date. Think of it as paying a token price to reserve the right to buy or sell the property at a pre-agreed specific price in the future. A call option gives the right to buy and represents a bullish bet, while a put option gives the right to sell.

Analysts use open interest as the measure of market size and participation – the higher the open interest, the deeper and more liquid the market.

Traders use options to hedge existing positions in the spot and futures markets, speculate on price direction, and generate additional income on coin/ETF holdings.

One of the most preferred income-generating strategies involving IBIT ETF and IBIT options is the covered call strategy. It allows investors to profit from BTC’s implied volatility by simultaneously holding the ETF and shorting IBIT calls at levels well above the ETF’s current market price.

Traders holding actual BTC have been doing this via Deribit for years.

Same in size but different in shape

The two markets, though, now match each other in scale but are positioned differently, revealing a lot about trader sentiment in each.

According to Volmex, the bulk of open interest in IBIT call options points to expectations of an ETF rallying to levels equivalent to BTC trading at $109,709 in the near-term. That’s roughly 41% higher than the current market price of $77,400.

Positioning in Deribit options is bullish but slightly measured, suggesting expectations of a rally to $106,000.

“Onshore call OI is concentrated roughly 4 percentage points further out-of-the-money than offshore, and the onshore average delta is slightly lower. This is consistent with onshore flow being dominated by retail upside speculation and systematic call overwriting programs, both of which concentrate OI in further-OTM strikes,” Volmex said in a report shared with CoinDesk.

ETF holders are more patient

Options have expiry dates – the point at which contracts are settled, depending on where IBIT or spot BTC is trading at that time.

Analysis of activity across both markets suggests that, on average, October 2026 expiries are preferred in IBIT, while August expiries dominate on Deribit.

“IBIT options are approximately two months longer-dated on an OI-weighted basis. The gap is roughly symmetric across puts and calls, suggesting it reflects the underlying holder base, longer-horizon ETF investors onshore versus more tactical positioning offshore, rather than asymmetric demand for protection or upside,” Volmex noted.

Lastly, IBIT’s implied volatility – a metric that measures expected swings in the BTC-linked ETF over the next four weeks – is higher than the implied volatility derived from Deribit’s BTC options.

Volmex attributes this premium to a structural quirk: Because ETF holders cannot easily short (express a bearish view) bitcoin directly, they buy put options as their only available hedge. This demand for put options is keeping IBIT’s implied volatility slightly elevated.

All things considered, IBIT’s rapid rise in the options market is striking and, in many ways, now appears to rival Deribit in scale. However, the two are not direct substitutes, as IBIT options primarily cater to regulated, onshore investors accessing bitcoin exposure through traditional brokerage channels, while Deribit remains the go-to place for global investors.

“I don’t see this as competition. If anything, it expands the market. As more participants get comfortable trading options via IBIT, it ultimately feeds into the broader ecosystem, and venues like Deribit benefit from increased sophistication and flow,” Fariq said.

Key Takeaways

• Advanced Micro Devices stock surged almost 14% Friday following Intel’s impressive Q1 earnings
• D.A. Davidson elevated AMD to Buy rating with a new $375 price target, up from $220
• Intel’s quarterly performance indicated strengthening CPU demand fueled by agentic AI adoption
• Jefferies analysts suggest AMD is capturing server market share from Intel
• AMD’s Q1 earnings report is scheduled for May 5

Shares of Advanced Micro Devices (AMD) delivered impressive gains Friday, surging nearly 14% to approximately $350 following Intel’s exceptional first-quarter earnings performance that energized the semiconductor sector.

Advanced Micro Devices, Inc., AMD

Intel’s quarterly results proved beneficial beyond its own stock price. The report signaled to investors that central processing unit demand is accelerating rapidly, positioning AMD as a prime beneficiary of this trend.

Gil Luria, analyst at D.A. Davidson, elevated his rating on AMD from Neutral to Buy while substantially increasing his price target from $220 to $375—a notable adjustment in a single research note.

Luria cited Intel’s earnings as the catalyst for his revised outlook. Intel delivered first-quarter revenue and profit figures that substantially exceeded Wall Street forecasts, with data center chip revenue showing particular strength.

The underlying catalyst? Agentic AI workloads. As artificial intelligence applications transition from training large language models to executing inference tasks—where models perform practical, real-world functions—CPUs have emerged as critical infrastructure components.

“We view Intel’s results as a precursor for a huge step-up for AMD’s CPU franchise,” Luria stated. He noted that the fundamental shift toward agentic AI is generating server CPU demand at unprecedented levels.

With demand projected to exceed supply availability, Luria also suggested AMD has opportunities to increase pricing throughout its CPU portfolio, potentially expanding profit margins and strengthening earnings capability.

AMD’s Competitive Position Against Intel

While Intel captured attention Friday with a 24% stock surge on its results, multiple analysts believe AMD may offer superior long-term investment potential.

Jefferies, which raised its Intel price target Thursday evening, indicated its strongest enthusiasm remains with AMD. The firm maintains a Buy rating and $300 price target on AMD, while keeping Intel at a Hold rating.

“INTC noted double-digit server unit growth with momentum extending into 2027, but AMD likely sees even better growth,” the Jefferies research team noted. They also highlighted AMD’s forthcoming Venice chips, anticipated in late 2026 or early 2027, as an important catalyst.

Morgan Stanley analyst Joseph Moore provided a more balanced perspective. Maintaining Equal Weight ratings on both companies, Moore suggested Intel’s earnings outperformance stemmed from supply limitations—not from Intel capturing market share from AMD.

Moore indicated the CPU “music is likely to keep playing for a while, as there is no indication that supply catches up to demand.”

Semiconductor Sector Momentum

AMD wasn’t the only chip stock posting substantial gains. Arm Holdings (ARM) also climbed nearly 15% Friday. Arm recently revealed intentions to manufacture its own CPU, intensifying competition with both Intel and AMD.

The PHLX Semiconductor Index advanced 4.5% during the session, marking its 18th consecutive positive trading day. The benchmark has climbed 43% in 2026 and more than 140% over the trailing 12 months.

AMD shares reached an intraday peak of $352.99 Friday, marking the stock’s highest level in over a year. The 52-week trading range extends from $91.87 to $352.99.

Advanced Micro Devices is scheduled to announce its first-quarter financial results on May 5, with an investor conference call commencing at 5:00 p.m. ET the same day.

TLDR:

• Solana Foundation is lending USDT to Aave for the first time to support the protocol’s ongoing recovery effort.
  
• Foundation Chair Lily Liu confirmed that the AAVE token will be integrated into the Solana network this weekend.
  
• The Solana Foundation has a history of deploying treasury funds to support DeFi protocols during critical recovery periods.
  
• Liu framed the cross-ecosystem move as a shared push toward open finance, using the phrase “DeFi United” on X.

Solana Foundation Chair Lily Liu has announced a new move to support DeFi ecosystem stability. The foundation is lending USDT to Aave for the first time as part of a broader recovery effort.

Liu also confirmed plans to bring the AAVE token to the Solana network this weekend. This marks a notable cross-chain gesture from one of crypto’s most active Layer 1 foundations.

Solana Foundation Steps Outside Its Own Ecosystem

The Solana Foundation has long used its treasury to support projects within the Solana network. However, this latest move signals a shift toward broader DeFi support. The foundation is now lending USDT directly into Aave, a leading Ethereum-based lending protocol.

Liu took to X to explain the rationale behind the decision. She wrote that economies do not exist in isolation and that Solana’s health depends on the health of all DeFi. That framing positioned the loan not as charity but as strategic ecosystem thinking.

The foundation has previously deployed treasury funds into Solana DeFi for several years. It also supported Tether’s recovery plan for Drift, a Solana-based trading platform. This Aave loan follows the same pattern of showing up during critical recovery periods.

AAVE Token Set to Launch on Solana This Weekend

Beyond the USDT loan, Liu confirmed that AAVE will be coming to the Solana network this weekend. This addition would make the governance token of one of DeFi’s largest protocols accessible on Solana. It also ties both announcements together under one broader strategy.

Bringing AAVE to Solana opens new opportunities for cross-chain liquidity and participation. Solana users would gain access to AAVE without leaving the network. That could drive additional trading volume and DeFi engagement on Solana.

Liu closed her post with the phrase “DeFi United,” framing the effort as a collaborative push across ecosystems. The Solana Foundation’s willingness to support a competitor’s recovery reflects a maturing approach to DeFi infrastructure. It treats the broader open finance movement as a shared goal rather than a zero-sum competition.

Key Takeaways

• AMD achieved record-breaking 2025 revenue totaling $34.6 billion featuring impressive data center expansion, whereas Intel reported $52.9 billion with no year-over-year movement
• The Data Center division at AMD generated $16.6 billion throughout 2025, propelled by EPYC server chip sales and AI-focused technologies
• Intel’s fiscal Q1 2026 revenue climbed 7% reaching $13.6 billion, though GAAP loss per share remained in negative territory at $(0.73)
• Analyst consensus positions AMD as a Moderate Buy with $296.44 average target price, whereas Intel carries a Hold rating at $72.98
• AMD represents the more reliable execution narrative; Intel remains positioned as a restructuring opportunity carrying greater risk

The semiconductor rivalry between Intel and AMD continues, yet 2025 market sentiment reveals starkly contrasting investor outlooks. One company demonstrates clear expansion momentum. The other represents a work-in-progress revival effort.

Let’s examine what the financial data reveals.

AMD’s Data Center Dominance

AMD delivered an exceptional 2025 performance. The semiconductor manufacturer announced all-time high annual revenue totaling $34.6 billion, achieving a 50% gross margin alongside $4.3 billion in net income. When measured on a non-GAAP basis, operating income reached $7.8 billion.

Advanced Micro Devices, Inc., AMD

The data center division emerged as the primary revenue catalyst. AMD’s Data Center operations generated $16.6 billion throughout 2025. This performance stemmed from accelerating demand for EPYC-branded server processors combined with the company’s artificial intelligence product portfolio.

AMD maintains diversified revenue streams beyond data centers. The Client and Gaming divisions contributed $14.6 billion combined, while Embedded products added another $3.5 billion. This multi-segment approach provides AMD with greater revenue stability compared to competitors dependent on narrower product categories.

Wall Street analysts have responded favorably. Among 40 analysts monitored by MarketBeat, 31 assign AMD a Buy recommendation and 1 rates it Strong Buy. The consensus 12-month price target stands at $296.44.

Intel’s Restructuring Journey

Intel maintains larger absolute revenue figures. The company’s full-year 2025 revenue totaled $52.9 billion, though this represented zero growth versus the prior year. Fourth-quarter revenue declined 4% to $13.7 billion.

Intel Corporation, INTC

The opening quarter of fiscal 2026 displayed modest progress. Revenue increased 7% year-over-year to $13.6 billion. However, Intel’s GAAP earnings per share remained in loss territory at $(0.73) for the period.

This persistent negative earnings position explains why Intel continues to be categorized as a “turnaround” opportunity rather than a “growth” investment by most market participants.

Intel retains significant advantages including operational scale, an established customer ecosystem, and strategic ambitions in contract chip manufacturing via its foundry operations. Yet investors are demanding these strategic initiatives deliver sustainable profitability before reassessing their outlook.

Analyst sentiment mirrors this cautious stance. Among 40 analysts tracking Intel, 25 assign a Hold rating, 11 recommend Buy, and 4 rate it Sell. The average price target stands at $72.98.

Intel’s latest quarterly results confirmed Q1 2026 performance: $13.6 billion revenue accompanied by a GAAP loss of $(0.73) per share.

Final Thoughts

These semiconductor competitors operate in overlapping markets while occupying dramatically different business trajectories. AMD currently demonstrates execution momentum. Intel leverages operational scale. Portfolio inclusion depends on whether investors prioritize demonstrated growth or restructuring upside potential.

Key Takeaways

• CRSP shares declined by as much as 11.59% during Friday’s session, touching an intraday low of $51.21
• First quarter results disappointed significantly: loss per share of -$1.37 versus analyst expectations of -$1.15; revenues of $0.86M compared to forecasts of $4.72M — representing a 97.8% year-over-year decline
• Competitive headwinds emerged as Regeneron announced its newly authorized gene therapy, Otarmeni, would be provided at no cost to qualifying patients in the United States, creating questions about Casgevy’s pricing sustainability
• Chief Executive Samarth Kulkarni divested 10,349 shares on March 16; company insiders collectively sold 51,828 shares during the previous three-month period
• Wall Street analysts continue to rate the stock as a consensus “Moderate Buy” with a mean price objective of $64.53

CRISPR Therapeutics ($CRSP) experienced a challenging trading session on Friday. Shares plummeted by as much as 11.59%, reaching an intraday bottom of $51.21, before closing near $51.04 — a significant decline from the previous day’s close of $55.18. Trading volume registered approximately 1.36 million shares, running about 27% lighter than typical daily activity.

CRISPR Therapeutics AG, CRSP

The sharp downturn stemmed from a confluence of negative catalysts: disappointing quarterly financial results and emerging competitive dynamics from Regeneron.

Regarding financial performance, CRISPR disclosed a loss per share of -$1.37 for the most recent quarter, falling short of Wall Street’s consensus projection of -$1.15. Revenues registered a mere $0.86 million — substantially below analyst forecasts of $4.72 million. This represented a staggering 97.8% contraction compared to the same period last year, surprising market participants.

The biotechnology firm’s return on equity remains negative at -26.31%, while its net margin continues to reflect deep losses. Wall Street analysts are currently projecting a full-year loss per share of -$4.93.

Regeneron’s Complimentary Gene Therapy Creates Competitive Headwinds

The secondary catalyst weighing on shares involves Regeneron’s latest development. The pharmaceutical company secured regulatory authorization for Otarmeni, a gene therapy it intends to distribute without charge to qualified U.S. patients. This represents a significant challenge to the broader gene-editing industry.

CRISPR’s primary commercial product, Casgevy — co-developed alongside Vertex Pharmaceuticals — commands a list price of $2.2 million. Investors are concerned that Regeneron’s zero-cost distribution strategy could reshape pricing dynamics throughout the sector, making it increasingly difficult for high-priced single-administration treatments to defend their valuations.

Casgevy achieved recognition as the inaugural CRISPR-based treatment to receive FDA authorization, representing a historic achievement. However, commercial adoption has progressed slower than anticipated, and Regeneron’s competitive move introduces additional questions regarding the revenue trajectory.

Executive Stock Sales Contribute to Investor Anxiety

Recent insider transactions haven’t bolstered investor confidence. Chief Executive Samarth Kulkarni disposed of 10,349 shares on March 16 at an average transaction price of $48.26, trimming his holdings by approximately 4%. General Counsel James Kasinger simultaneously sold 3,450 shares on the identical date.

During the preceding three-month window, company insiders have collectively divested 51,828 shares, generating approximately $2.58 million in proceeds. Internal stakeholders currently control 4.30% of outstanding shares.

While such divestment activity isn’t uncommon among biotech executives managing equity-based compensation packages, it contributes to the cautious atmosphere surrounding the shares.

From an analyst perspective, the outlook remains somewhat divided but generally supportive. Bank of America maintains a Buy recommendation with an $89 price objective. Needham carries a Buy rating alongside an $82 target. TD Cowen holds a neutral Hold stance with a $45 projection. Citizens JMP assigns a Market Outperform rating with an $80 target. The aggregate consensus lands at Moderate Buy, featuring an average price target of $64.53 — considerably above present trading levels.

The equity’s 50-day moving average registers at $52.68 while the 200-day average stands at $55.70. The company’s market capitalization approximates $4.90 billion with a beta coefficient of 1.80.

Current price action shows CRSP trading around $51, remaining beneath both critical moving average benchmarks.

Key Highlights

• Nvidia’s shares reached an unprecedented closing price of $208.27 on Friday, marking a 4.3% gain
• The company’s valuation surpassed $5 trillion, reclaiming its status as the globe’s largest publicly traded corporation
• Intel’s exceptional quarterly results — posting its strongest single-day gain since 1987 with a 24% surge — ignited momentum across semiconductor stocks
• AMD shares soared 14% while Qualcomm advanced 11% during the same trading session
• Wall Street consensus among 42 analysts shows a Strong Buy rating, with a mean price target of $273.57

On Friday, April 24, Nvidia achieved a historic milestone by closing at its highest price ever recorded. The stock advanced 4.3% to finish at $208.27, elevating its total market capitalization beyond the $5 trillion threshold.

NVIDIA Corporation, NVDA

This achievement positions Nvidia as the planet’s most valuable publicly listed enterprise — once more.

The rally was catalyzed by Intel’s quarterly earnings announcement, which came after Thursday’s market close. Intel exceeded analyst projections, propelling its shares upward by 24% on Friday — marking the company’s most impressive daily gain in nearly four decades.

This positive sentiment rippled through the semiconductor industry. AMD jumped 14% and Qualcomm climbed 11%.

Nvidia initially breached the $5 trillion market cap threshold on October 29, 2025. The company had earlier reached $4 trillion on July 9, 2025 — less than twelve months prior.

Merely three years have passed since Nvidia’s valuation first exceeded $1 trillion. The trajectory of expansion has been extraordinary.

Nasdaq Poised for Strongest Monthly Gain Since April 2020

The Nasdaq composite index has surged 15% throughout April, positioning it for its most robust monthly showing in six years. Large-capitalization technology stocks have regained investor attention following a correction fueled by escalating oil prices connected to the Iran conflict and associated supply chain disruptions.

NVDA has multiplied more than fourteen times since December 2022 ended. In the past month alone, shares have appreciated nearly 20%.

Capital has been flowing back into growth-oriented equities, as artificial intelligence infrastructure requirements continue accelerating. Nvidia’s graphics processing units remain the preferred hardware solution for Google, Microsoft, Meta, Amazon, OpenAI, and Anthropic.

Competitive Pressures Intensifying

Alphabet, among Nvidia’s most significant clients, revealed new proprietary chips designed to rival Nvidia’s offerings when they launch for cloud platform customers in the coming months.

Nevertheless, Wall Street sentiment stays overwhelmingly positive. Among 42 equity analysts tracking the stock, 40 recommend Buy, one suggests Hold, and one advises Sell.

The consensus price target stands at $273.57 — suggesting approximately 31% potential appreciation from Friday’s closing price.

Mythos, the new AI model from Anthropic that has sparked fear and confusion in traditional tech and finance, is also driving a massive shift in how the crypto industry thinks about security.

For years, decentralized finance has focused its defenses on smart contracts. Code is audited, vulnerabilities are cataloged, and many common exploits are well understood. But Mythos, a model designed to identify and chain together weaknesses across systems, is pushing attention beyond code and into the infrastructure that supports it.

“The bigger risks sit in infrastructure,” said Paul Vijender, head of security at Gauntlet, a risk management firm. “When I think about AI-driven threats, I’m less concerned about smart contract exploits and more focused on AI-assisted attacks against the human and infrastructure layers.”

That includes key management systems, signing services, bridges, oracle networks, and the cryptographic layers that connect them. These components are less visible than smart contracts and are often outside traditional audit scope.

In fact, this month, web infrastructure provider Vercel, which many crypto companies use, disclosed a security breach that may have exposed customer API keys, prompting crypto projects to rotate credentials and review their code. Vercel traced the intrusion to a compromised Google Workspace connection via the third-party AI tool Context.ai, which an employee used.

Mythos belongs to a new class of AI systems built to simulate adversaries. Instead of scanning for known bugs, it explores how protocols interact, testing how small weaknesses can be combined into real-world exploits. That approach has drawn attention beyond crypto. Banks like JP Morgan are increasingly treating AI-driven cyber risk as systemic and are exploring tools like Mythos for stress testing. Earlier this month, Coinbase and Binance both reportedly approached Anthropic to test Mythos.

Early findings from models like Mythos have identified weaknesses in the behind-the-scenes systems that keep crypto platforms secure, including the technology that protects keys and handles communication between systems.

“I think there are two areas where AI models are especially valuable,” Vijender said. “First, multi-step exploit chains that historically only get discovered after money is lost. Second, infrastructure-layer vulnerabilities that traditional audits never touch.”

That shift matters in a system built on composability, where DeFi protocols can connect and build on each other’s services.

DeFi protocols are designed to interconnect. They share liquidity, rely on common oracles, and interact through layers of integrations that are difficult to map in full. That interconnectedness has driven growth, but it also creates pathways for risk to spread, as seen in recent bridge exploits like the Hyperbridge attack, in which an attacker minted $1 billion worth of bridged Polkadot tokens on Ethereum by exploiting a flaw in how cross-chain messages were verified.

“Composability is what makes DeFi capital efficient and innovative,” Vijender said. “But it also means a minor vulnerability in one protocol can become a critical exploit vector with contagion potential across the ecosystem.”

Without AI, those dependencies are hard to trace. With AI, they can be mapped and exploited at scale. The result is a shift from isolated exploits to systemic failures that cascade across protocols.

Evolution of AI attacks

Still, some industry leaders see Mythos as an acceleration rather than a turning point.

At Aave Labs, founder Stani Kulechov said AI reflects the dynamics already at play in DeFi’s adversarial environment.

“Web3 is no stranger to well-funded and motivated adversaries,” he told CoinDesk. “AI models represent an evolution in the tools used to achieve exploits.”

From that perspective, DeFi is already built for machine-speed attacks. Smart contracts execute automatically, and defenses such as liquidation mechanisms and risk parameters operate without human intervention.

“DeFi operates at compute speed, so AI doesn’t introduce a new dynamic,” Kulechov said. “It intensifies an environment that has always required constant vigilance.”

Even so, Aave is seeing AI surface new categories of vulnerabilities, including issues that human auditors may have previously deprioritized.

“The Mythos paper shows that AI can uncover old bugs that were previously deprioritized,” he said.

That breadth still matters in a system where even smaller vulnerabilities can undermine trust or be combined into larger exploits.

If attackers can move faster, the question becomes whether defenses can keep pace.

For both Gauntlet and Aave, the answer lies in changing the security model itself. Audits before deployment and monitoring after were designed for human-paced threats. AI compresses that timeline.

“To defend against offensive AI, we will need to take an AI-centric approach where speed and continuous adaptation are essential,” Vijender of Gauntlet said. That includes continuous auditing, real-time simulation, and systems built with the assumption that breaches will happen.

A ‘greater way’

Aave has already integrated AI into its workflows, using it for simulations and code review alongside human auditors. “We take an AI-first approach where it adds clear value,” Kulechov of Aave Labs said. “But it complements, rather than replaces, human-led auditing.”

In that sense, AI equips both attackers and defenders.

For builders, the long-term effect may be less disruption than divergence.

“We haven’t tested Mythos yet, but we’re genuinely interested in what it and tools like it can do for protocol security,” said Hayden Adams, founder and CEO of Uniswap Labs. “AI gives builders better ways to stress test and harden systems.”

Over time, Adams expects the gap between secure and insecure protocols to widen.

“Projects that prioritize security will have greater ability to test and harden systems before launching,” he said. “Projects that don’t will be most at risk.”

That may be the real shift. Security is no longer about eliminating vulnerabilities. It is about continuously adapting to a system in which those vulnerabilities are constantly rediscovered and recombined.

Read more: Move over bitcoin and quantum risks. Anthropic’s Mythos AI could have major implications for DeFi

The regulatory fight over prediction markets moved to the federal courts this week as the Commodity Futures Trading Commission (CFTC) sued New York state to block its gambling-law actions from applying to federally regulated event-contract platforms. In the Southern District of New York, the CFTC argued that federal law grants it exclusive authority over these markets and asked for a declaratory judgment plus a permanent injunction against New York’s enforcement efforts.

“CFTC-registered exchanges have faced an onslaught of state lawsuits seeking to limit Americans’ access to event contracts and undermine the CFTC’s sole regulatory jurisdiction over prediction markets,” said CFTC Chair Michael Selig. The complaint comes as New York has intensified its own actions against major platforms, including Coinbase and Gemini, with Kalshi having faced prior state-enforcement pressure on its sports-related contracts.

For context, New York’s push against unregistered gambling or gaming activities has been part of a broader state-led wave targeting prediction-market operators. Earlier this week, New York filed suits against Coinbase and Gemini, alleging unlicensed gambling activity. Kalshi, a prominent prediction platform, has also faced regulatory moves in the past. Related coverage has highlighted related enforcement actions in other jurisdictions and ongoing debates about the boundaries between federal financial regulation and state gambling rules.

Key takeaways

• The CFTC asserts exclusive federal jurisdiction over prediction markets and seeks a judicial ruling that New York cannot enforce its gambling rules against federally regulated platforms.
• New York has separately pursued enforcement actions against prominent platforms, illustrating a broader state-led crackdown on prediction-market offerings.
• A coalition of 37 states and Washington, D.C. filed an amicus brief backing Massachusetts in its Kalshi case, arguing federal law does not clearly override state gambling authority.
• Kalshi contends its products are “swaps” regulated under a 2010 financial law, while states argue that the law was not intended to legalize nationwide sports betting or preempt state protections.
• The evolving landscape signals greater regulatory fragmentation for prediction markets, with potential implications for users, developers, and investors.

Federal authority under dispute

The CFTC’s filing in SDNY centers on whether New York’s enforcement actions against prediction-market platforms can stand alongside federal supervision of these markets. The agency asserts that federal law grants it exclusive authority over prediction markets and that state actions risk “undermining the CFTC’s sole regulatory jurisdiction.” The CFTC’s move underscores a broader tension between federal oversight and state gambling regulations as platforms offer event-based contracts tied to real-world outcomes.

In presenting its case, the CFTC highlighted what it sees as a pattern of state-level lawsuits aimed at limiting access to these markets. The agency framed its suit as a necessary step to preserve a uniform federal framework for prediction markets and to prevent a patchwork of state rules that could complicate compliance for federally registered exchanges.

The developing legal dispute sits at the intersection of financial regulation and gambling policy, inviting questions about how federal authority should apply to products that blend financial mechanics with event-betting features. Observers will be watching not only the SDNY proceedings but also how state courts interpret the reach of federal financial statutes in relation to traditional gambling authority.

Massachusetts case and the 37-state amicus brief

In a parallel but closely related thread, a coalition of 37 states and Washington, D.C. filed an amicus brief supporting Massachusetts in its challenge to Kalshi’s sports-betting stance. The filing urges Massachusetts’ highest court to reject Kalshi’s argument that federal law permits nationwide sports betting without adhering to state rules. The amicus brief is available from the Massachusetts attorney general’s office: 37-state backing Massachusetts in Kalshi matter.

Kalshi maintains that its betting products are swaps regulated under a 2010 financial law, a position it frames as federal coverage for certain exchange-traded event contracts. States counter that the law in question was never intended to authorize the expansion of sports betting nationwide or to supersede established state gambling regimes. The states contend that preserving state oversight remains essential for protections such as licensing, age restrictions, fraud prevention, and gambling-addiction safeguards—areas not addressed by federal financial regulation.

Previous coverage has noted that the Kalshi case sits at a critical juncture for the broader debate over federal preemption in financial markets and the role of states in policing everyday gambling-related services. The amicus brief signals a broad, organized effort by state attorneys general to shape how federal law interacts with state gambling controls in the context of prediction markets.

State crackdowns intensify across jurisdictions

The past several months have seen a sharpened stance from states against prediction-market operators. Arizona, Connecticut, and Illinois have pursued efforts to enforce gambling laws against platforms offering prediction contracts. In some cases, regulators have issued cease-and-desist orders or pursued court action to curb unregistered offerings. This trend reflects a growing belief among state authorities that prediction markets straddle long-standing lines between gambling regulation and financial product oversight.

Earlier this month, a Nevada judge extended a prohibition on Kalshi’s event-based contracts within the state, siding with regulators who argued that the products function as unlicensed gambling. The Nevada ruling adds to a string of state-level actions that complicate the operating environment for prediction-market platforms and their users.

These developments come amid broader conversations about how to balance consumer protections with innovative financial instruments. While some observers see potential benefits in prediction markets for information discovery and hedging, others warn of regulatory and compliance risks that could constrain adoption and scale.

As coverage from Cointelegraph and other outlets has noted, the tension between federal preemption and state gambling authority is not new, but the current convergence of high-profile suits, amicus briefs, and court decisions raises the stakes for Kalshi, Polymarket, and similar platforms that tether financial mechanics to live events. The evolving legal framework will likely shape how next-generation prediction services design compliance programs and engage with regulators going forward.

What happens next will hinge on courtroom decisions in the SDNY action and in state courts handling Kalshi’s case. Investors, operators, and users should monitor regulatory filings and rulings closely, as outcomes could redefine the permissible scope of prediction markets in the United States and influence how these platforms structure products, licensing, and risk controls going forward.